1778
PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and ribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment.
 ( adverse event: developed ,  A 34-year-old woman with chronic hepatitis C, genotype 3: Subject, 34-year-old: Subject.Age, woman: Subject.Gender, genotype 3: Subject.Disorder, progressive malaise and anemia: Effect, pegylated interferon alpha-2a and ribavirin for 6 months: Treatment, 6 months: Treatment.Duration, pegylated interferon alpha-2a: Treatment.Drug, ribavirin: Treatment.Drug, 6 months: Treatment.Time_elapsed, chronic hepatitis C: Treatment.Disorder, ribavirin: Combination.Drug, pegylated interferon alpha-2a: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: developed ,  A 34-year-old woman with chronic hepatitis C, genotype 3: Subject, 34-year-old: Subject.Age, woman: Subject.Gender, genotype 3: Subject.Disorder, progressive malaise and anemia: Effect, pegylated interferon alpha-2a and ribavirin for 6 months: Treatment, 6 months: Treatment.Duration, pegylated interferon alpha-2a: Treatment.Drug, ribavirin: Treatment.Drug, 6 months: Treatment.Time_elapsed, chronic hepatitis C: Treatment.Disorder, ribavirin: Combination.Drug, pegylated interferon alpha-2a: Combination.Drug) 